It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAAD shows. In the Phase 3 ALCANZA trial, Seattle Genetics' and Takeda's ADCETRIS was associated with a statistically significant improvement in the objective response rate in subjects with CTCL. Valeant Pharmaceuticals' SILIQ injection of brodalumab will be priced at $3,500 per month, making it the least expensive injectable biologic psoriasis treatment currently on the market, the company says.